Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 20Rectal Neoplasms 11Colonic Neoplasms 9Neoplasm Metastasis 7Carcinoma, Hepatocellular 6Pancreatic Neoplasms 5Stomach Neoplasms 4Recurrence 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Motor Activity 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Esophagogastric Cancer 1Esophageal Squamous Cell Carcinoma 1Clinical Stage I Gastric Cancer AJCC v8 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Borderline Resectable Pancreatic Adenocarcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Esophagogastric Cancer × Oxaliplatin × Clear all
NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡